NASDAQ:AYTU Aytu BioPharma Q1 2027 Earnings Results & Report $2.66 0.00 (0.00%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$2.66 -0.01 (-0.19%) As of 11/20/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Aytu BioPharma beat analyst expectations on both earnings and revenue in its Q1 2027 results, released November 16, 2026. The company reported EPS of -$0.20 versus the -$0.2567 consensus estimate, while revenue of $14.84 million topped the $13.27 million estimate by $1.57 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2027Report DateNovember 16, 2026TimeAfter Market ClosesConference Call4:30 PM ET Aytu BioPharma EPS ResultsActual EPS-$0.20Consensus EPS -$0.2567Beat/MissBeat by +$0.0567One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersAytu BioPharma Revenue ResultsActual Revenue$14.84 millionExpected Revenue$13.27 millionBeat/MissBeat by +$1.57 millionYoY Revenue GrowthN/AUpcoming EarningsAytu BioPharma's Q2 2027 earnings is estimated for Tuesday, February 2, 2027, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aytu BioPharma Q1 2027 Earnings FAQ Did Aytu BioPharma beat earnings estimates for Q1 2027? Aytu BioPharma (NASDAQ:AYTU) reported earnings of -$0.20 per share for Q1 2027, beating the consensus estimate of -$0.2567. The report was announced on Monday, November 16, 2026. What was Aytu BioPharma's revenue for Q1 2027? Aytu BioPharma reported revenue of $14.84 million for Q1 2027, against a consensus estimate of $13.27 million. When is Aytu BioPharma's next earnings date? Aytu BioPharma's next earnings date is estimated for Tuesday, February 2, 2027. MarketBeat tracks confirmed and estimated earnings dates for Aytu BioPharma on the company's earnings history page. Aytu BioPharma Earnings HeadlinesAytu BioPharma (AYTU) Stock Sees Fair Value Lift After Rosemont Deal Recast Analyst ViewsNovember 19 at 2:21 PM | finance.yahoo.comAytu BioPharma (NASDAQ:AYTU) Shares Break Above 200-Day Moving Average on Analyst DowngradeNovember 19 at 2:10 AM | americanbankingnews.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 21 at 1:00 AM | Profits Run (Ad)Aytu BioPharma (NASDAQ:AYTU) Stock Rating Lowered by Maxim GroupNovember 19 at 1:24 AM | americanbankingnews.comAytu BioPharma (NASDAQ:AYTU) Stock Rating Lowered by Lake Street CapitalNovember 19 at 1:24 AM | americanbankingnews.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aytu BioPharma, Inc. (NASDAQ: AYTU)November 18 at 11:18 AM | prnewswire.comSee More Aytu BioPharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aytu BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aytu BioPharma and other key companies, straight to your email. Email Address About Aytu BioPharmaAytu BioPharma (NASDAQ:AYTU), Inc. is a specialty pharmaceutical company focused on developing and commercializing prescription treatments. Its business has centered on medicines for attention-deficit/hyperactivity disorder (ADHD) and other pediatric conditions. The company’s product portfolio has included ADHD medications such as Adzenys XR-ODT, an orally disintegrating amphetamine tablet, and Cotempla XR-ODT, an extended-release methylphenidate tablet. Aytu has also marketed treatments for other pediatric needs, including allergies. Aytu’s commercial activities have primarily served the U.S. market. The company has grown through acquisitions, including the 2021 acquisition of Neos Therapeutics, which added ADHD products to its portfolio.View Aytu BioPharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestHard Drives Were Left for Dead, But Seagate and Western Digital Are SoaringPalo Alto Networks' Q1 Beat Gives Its Stock Rally Another Reason to RunGrand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.